A selective endothelin ETA receptor antagonist, SB 234551, improves cerebral perfusion following permanent focal cerebral ischemia in rats

Yongbo Zhang, Ludmila Belayev, Weizhao Zhao, Elaine A. Irving, Raul Busto, Myron Ginsberg

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

In recent experimental studies, a selective antagonist of endothelin ETA receptors, SB 234551, improved neurological and histological outcome in both head trauma and transient focal cerebral ischemia. The present study was conducted to ascertain the degree to which hemodynamic alterations are responsible for this therapeutic effect in a model of permanent middle cerebral artery occlusion (MCAo) in rats. Anesthetized Sprague-Dawley rats were subjected to permanent MCAo by insertion of an intraluminal nylon suture coated with poly-l-lysine. The agent (SB 234551, 30 μg/kg/min = 1.8 mg/kg/h) or vehicle (PBS; 0.6 ml/h) was administered by i.v. infusion beginning 15 min after onset of MCAo and lasting for 23.75 h. Autoradiographic measurement of local cerebral blood flow (lCBF) was performed at 24 h. Physiological data were similar among groups. SB 234551 augmented perfusion by 1.7- to 1.8-fold in both the ischemic hemisphere and in the contralateral (non-ischemic) hemisphere when compared to vehicle-treated ischemic animals. In the ischemic hemisphere, the brain regions significantly benefited were those lying outside the zone of most dense ischemia (i.e., paramedian cortex and thalamus), while in the non-ischemic hemisphere all regions measured showed significant lCBF augmentation. This study demonstrates that SB 234551 therapy results in significant improvement of local cerebral perfusion in the ischemic as well as in the non-ischemic hemispheres after permanent MCAo.

Original languageEnglish
Pages (from-to)150-156
Number of pages7
JournalBrain Research
Volume1045
Issue number1-2
DOIs
StatePublished - May 31 2005

Fingerprint

Middle Cerebral Artery Infarction
Brain Ischemia
Cerebrovascular Circulation
Perfusion
Nylons
Transient Ischemic Attack
Therapeutic Uses
Thalamus
Craniocerebral Trauma
Sutures
Lysine
Sprague Dawley Rats
Ischemia
Hemodynamics
Endothelin Receptor Antagonists
SB 234551
Brain
Therapeutics

Keywords

  • Animal model
  • Focal cerebral ischemia
  • Neuroprotection
  • Stroke

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

A selective endothelin ETA receptor antagonist, SB 234551, improves cerebral perfusion following permanent focal cerebral ischemia in rats. / Zhang, Yongbo; Belayev, Ludmila; Zhao, Weizhao; Irving, Elaine A.; Busto, Raul; Ginsberg, Myron.

In: Brain Research, Vol. 1045, No. 1-2, 31.05.2005, p. 150-156.

Research output: Contribution to journalArticle

@article{3379eca85f9240248d754b1e7ced8fbd,
title = "A selective endothelin ETA receptor antagonist, SB 234551, improves cerebral perfusion following permanent focal cerebral ischemia in rats",
abstract = "In recent experimental studies, a selective antagonist of endothelin ETA receptors, SB 234551, improved neurological and histological outcome in both head trauma and transient focal cerebral ischemia. The present study was conducted to ascertain the degree to which hemodynamic alterations are responsible for this therapeutic effect in a model of permanent middle cerebral artery occlusion (MCAo) in rats. Anesthetized Sprague-Dawley rats were subjected to permanent MCAo by insertion of an intraluminal nylon suture coated with poly-l-lysine. The agent (SB 234551, 30 μg/kg/min = 1.8 mg/kg/h) or vehicle (PBS; 0.6 ml/h) was administered by i.v. infusion beginning 15 min after onset of MCAo and lasting for 23.75 h. Autoradiographic measurement of local cerebral blood flow (lCBF) was performed at 24 h. Physiological data were similar among groups. SB 234551 augmented perfusion by 1.7- to 1.8-fold in both the ischemic hemisphere and in the contralateral (non-ischemic) hemisphere when compared to vehicle-treated ischemic animals. In the ischemic hemisphere, the brain regions significantly benefited were those lying outside the zone of most dense ischemia (i.e., paramedian cortex and thalamus), while in the non-ischemic hemisphere all regions measured showed significant lCBF augmentation. This study demonstrates that SB 234551 therapy results in significant improvement of local cerebral perfusion in the ischemic as well as in the non-ischemic hemispheres after permanent MCAo.",
keywords = "Animal model, Focal cerebral ischemia, Neuroprotection, Stroke",
author = "Yongbo Zhang and Ludmila Belayev and Weizhao Zhao and Irving, {Elaine A.} and Raul Busto and Myron Ginsberg",
year = "2005",
month = "5",
day = "31",
doi = "10.1016/j.brainres.2005.03.025",
language = "English",
volume = "1045",
pages = "150--156",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - A selective endothelin ETA receptor antagonist, SB 234551, improves cerebral perfusion following permanent focal cerebral ischemia in rats

AU - Zhang, Yongbo

AU - Belayev, Ludmila

AU - Zhao, Weizhao

AU - Irving, Elaine A.

AU - Busto, Raul

AU - Ginsberg, Myron

PY - 2005/5/31

Y1 - 2005/5/31

N2 - In recent experimental studies, a selective antagonist of endothelin ETA receptors, SB 234551, improved neurological and histological outcome in both head trauma and transient focal cerebral ischemia. The present study was conducted to ascertain the degree to which hemodynamic alterations are responsible for this therapeutic effect in a model of permanent middle cerebral artery occlusion (MCAo) in rats. Anesthetized Sprague-Dawley rats were subjected to permanent MCAo by insertion of an intraluminal nylon suture coated with poly-l-lysine. The agent (SB 234551, 30 μg/kg/min = 1.8 mg/kg/h) or vehicle (PBS; 0.6 ml/h) was administered by i.v. infusion beginning 15 min after onset of MCAo and lasting for 23.75 h. Autoradiographic measurement of local cerebral blood flow (lCBF) was performed at 24 h. Physiological data were similar among groups. SB 234551 augmented perfusion by 1.7- to 1.8-fold in both the ischemic hemisphere and in the contralateral (non-ischemic) hemisphere when compared to vehicle-treated ischemic animals. In the ischemic hemisphere, the brain regions significantly benefited were those lying outside the zone of most dense ischemia (i.e., paramedian cortex and thalamus), while in the non-ischemic hemisphere all regions measured showed significant lCBF augmentation. This study demonstrates that SB 234551 therapy results in significant improvement of local cerebral perfusion in the ischemic as well as in the non-ischemic hemispheres after permanent MCAo.

AB - In recent experimental studies, a selective antagonist of endothelin ETA receptors, SB 234551, improved neurological and histological outcome in both head trauma and transient focal cerebral ischemia. The present study was conducted to ascertain the degree to which hemodynamic alterations are responsible for this therapeutic effect in a model of permanent middle cerebral artery occlusion (MCAo) in rats. Anesthetized Sprague-Dawley rats were subjected to permanent MCAo by insertion of an intraluminal nylon suture coated with poly-l-lysine. The agent (SB 234551, 30 μg/kg/min = 1.8 mg/kg/h) or vehicle (PBS; 0.6 ml/h) was administered by i.v. infusion beginning 15 min after onset of MCAo and lasting for 23.75 h. Autoradiographic measurement of local cerebral blood flow (lCBF) was performed at 24 h. Physiological data were similar among groups. SB 234551 augmented perfusion by 1.7- to 1.8-fold in both the ischemic hemisphere and in the contralateral (non-ischemic) hemisphere when compared to vehicle-treated ischemic animals. In the ischemic hemisphere, the brain regions significantly benefited were those lying outside the zone of most dense ischemia (i.e., paramedian cortex and thalamus), while in the non-ischemic hemisphere all regions measured showed significant lCBF augmentation. This study demonstrates that SB 234551 therapy results in significant improvement of local cerebral perfusion in the ischemic as well as in the non-ischemic hemispheres after permanent MCAo.

KW - Animal model

KW - Focal cerebral ischemia

KW - Neuroprotection

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=19444369869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19444369869&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2005.03.025

DO - 10.1016/j.brainres.2005.03.025

M3 - Article

VL - 1045

SP - 150

EP - 156

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1-2

ER -